Abstract 2459
Background
Arthralgia and myalgia are described with the vascular endothelial growth factor inhibitor Bevacizumab (Bev). However, in clinical practice these pains are not spontaneously reported by patients. We aimed to evaluate the frequency of arthralgia in patients treated by Bev and identify risk factors associated with arthralgia.
Methods
We conducted an observational, prospective, bicentric, health data study in two French centers. Self-administered questionnaires were distributed to patients at the initiation of Bev, at 3 months and at 6 months during treatment. We included patients treated for ovarian, colorectal or lung cancers. Bev (5 to 15 mg/kg) was administered intravenously every 2 or 3 weeks with chemotherapy most of the time.
Results
We included 71 patients from January 2018 to November 2018 (42 patients with colorectal cancer, 22 with ovarian cancer and 7 with lung cancer). Seventy-one patients completed the questionnaire at initiation, 56 (78,9%) at 3 months and 36 (50,7%) at 6 months. The frequency of joint pain before Bev initiation was 29,6% and increase at 3 months (41,8%, p = 0,18) and significantly at 6 months (50%, p = 0,04). The functional repercussion significantly increased for elementary activities from 5,9% at initiation to 12,7% at 3 months (p < 0,001) and to 16,7% at 6 months (p < 0,001). There was no difference for instrumental activities at 3 months (p = 0,07) and at 6 months (p = 0,07). In univariate analysis, the frequency of arthralgia increased significantly at 3 months for patients with Body Mass Index (BMI) > 25 kg/m2 (p = 0,04), ovarian cancer (p < 0,001), chemotherapy with Carboplatin (p = 0,01) and Paclitaxel (p < 0,001), 15 mg/kg dose of Bev (p < 0,001). At 6 months, women (p = 0,03), chemotherapy with carboplatin (p < 0,001) and paclitaxel (p < 0,001), 15 mg/kg dose of Bev (p < 0,001) were significantly associated with arthralgia occurrence. Nineteen patients (26,8%) wished to consult a rheumatologist.
Conclusions
Bevacizumab-associated protocols are responsible for a significant increase of arthralgia frequency in women treated for an ovarian cancer. The pain appears in the first 3 months and increase during treatment. Oncologists should be aware of this side effect in order to inform the patients and propose a suitable treatment.
Clinical trial identification
NCT03455907.
Editorial acknowledgement
Legal entity responsible for the study
Vieillard Marie-Hélène.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1728 - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
Presenter: Hironobu Hashimoto
Session: Poster Display session 1
Resources:
Abstract
920 - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Presenter: Lee Schwartzberg
Session: Poster Display session 1
Resources:
Abstract
5146 - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
Presenter: Smitha Saldanha
Session: Poster Display session 1
Resources:
Abstract
1947 - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients - A prospective multicenter trial
Presenter: Meinolf Karthaus
Session: Poster Display session 1
Resources:
Abstract
6163 - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy
Presenter: Hee Jun Kim
Session: Poster Display session 1
Resources:
Abstract
2154 - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.
Presenter: Teresa Smit
Session: Poster Display session 1
Resources:
Abstract
1637 - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)”
Presenter: Jyoti Bajpai
Session: Poster Display session 1
Resources:
Abstract
5351 - Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.
Presenter: David Pesántez Coronel
Session: Poster Display session 1
Resources:
Abstract
1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
Presenter: Shota Omori
Session: Poster Display session 1
Resources:
Abstract
4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.
Presenter: Diego Muñoz Guglielmetti
Session: Poster Display session 1
Resources:
Abstract